NOT_YET_RECRUITING

NT-3 Levels and Function in Individuals With CMT

Talk to us

Conditions

Charcot-Marie-Tooth DiseasePeripheral NeuropathyChronic Inflammatory Demyelinating PolyneuropathyNT-3CMT1ANeuropathy

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study will assess the serum NT-3 levels in individuals with the diagnosis of peripheral neuropathy or any type of Charcot-Marie-Tooth Neuropathy (CMT) and correlate this with function.

Official Title

Correlation of Circulating NT-3 Levels and Function in Individuals With Peripheral Neuropathy or Charcot-Marie-Tooth Neuropathy

Quick Facts

Study Start:2027-11-13
Study Completion:2030-06
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:NOT_YET_RECRUITING

Study ID

NCT05011006

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:7 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Males or females from 7 years of age or older
  2. * Diagnosis of acquired peripheral neuropathy (PN) such as due to diabetes, chemo-induced, autoimmune chronic inflammatory demyelinating polyneuropathy (CIDP) established by a report of electrical studies or with a known genetic CMT diagnosis. Definitive diagnosis of PN is established with a report of electrical studies, EMG/nerve conduction studies.2
  3. * Perform assessments to the best of their ability with reliable results as deemed by the evaluator.
  4. * Ability to attend scheduled appointments
  5. * Ability to provide informed consent (or assent for ages 9-18)
  1. * Current pregnancy per medical history
  2. * Has a medical condition or extenuating circumstances that, in the opinion of the investigator, might compromise the subject's wellbeing, safety, or clinical interpretability

Contacts and Locations

Study Contact

Dawn Scott, RN
CONTACT
614722-2715
Dawn.Scott@nationwidechildrens.org

Principal Investigator

Zarife Sahenk, MD., PhD.
PRINCIPAL_INVESTIGATOR
Nationwide Children's Hospital

Study Locations (Sites)

Nationwide Children's Hospital
Columbus, Ohio, 43205
United States

Collaborators and Investigators

Sponsor: Zarife Sahenk

  • Zarife Sahenk, MD., PhD., PRINCIPAL_INVESTIGATOR, Nationwide Children's Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2027-11-13
Study Completion Date2030-06

Study Record Updates

Study Start Date2027-11-13
Study Completion Date2030-06

Terms related to this study

Keywords Provided by Researchers

  • NT-3
  • CMT1A
  • Neuropathy

Additional Relevant MeSH Terms

  • Charcot-Marie-Tooth Disease
  • Peripheral Neuropathy
  • Chronic Inflammatory Demyelinating Polyneuropathy